Adelman Robert J

CIK 000132916113 companiesSAN FRANCISCO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001329161

Recent Transactions

50 trades

Purchase
Artiva Biotherapeutics, Inc.$ARTV
Common Stock
2024-07-22$12.00/sh+416,666→ 1,936,637 total
Conversion
Artiva Biotherapeutics, Inc.$ARTV
Series A Convertible Preferred Stock
2024-07-22−843,592→ 0 total
Conversion
Artiva Biotherapeutics, Inc.$ARTV
Common Stock
2024-07-22+843,592→ 843,592 total
Other
Artiva Biotherapeutics, Inc.$ARTV
Common Stock
2024-07-22+461,687→ 1,519,971 total
Conversion
Artiva Biotherapeutics, Inc.$ARTV
Common Stock
2024-07-22+214,692→ 1,058,284 total
Conversion
Artiva Biotherapeutics, Inc.$ARTV
Series B Convertible Preferred Stock
2024-07-22−214,692→ 0 total
Conversion
RayzeBio, Inc.
Common Stock
2023-09-19+247,343→ 5,158,162 total
Conversion
RayzeBio, Inc.
Series A Convertible Preferred Stock
2023-09-19−3,786,957→ 0 total
Conversion
RayzeBio, Inc.
Series B Convertible Preferred Stock
2023-09-19−1,123,862→ 0 total
Conversion
RayzeBio, Inc.
Common Stock
2023-09-19+3,786,957→ 3,786,957 total
Conversion
RayzeBio, Inc.
Series C Convertible Preferred Stock
2023-09-19−216,127→ 0 total
Conversion
RayzeBio, Inc.
Common Stock
2023-09-19+1,123,862→ 4,910,819 total
Award
Ventyx Biosciences, Inc.$VTYX
Stock Option (right to buy)
2022-06-09+13,301→ 13,301 total
Award
Ventyx Biosciences, Inc.$VTYX
Stock Option (right to buy)
2022-06-09+13,301→ 13,301 total
Sale
Elevation Oncology, Inc.
Common Stock
2022-05-25$4.12/sh−702,737→ 1,905,430 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-05-16$10.45/sh−95,800→ 2,155,930 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-05-13$10.45/sh−35,850→ 2,251,730 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-05-12$10.39/sh−124,525→ 2,287,580 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-05-11$10.38/sh−17,700→ 2,412,105 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-05-10$10.38/sh−18,676→ 2,429,805 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-05-09$10.37/sh−17,600→ 2,448,481 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-05-06$10.37/sh−48,334→ 2,466,081 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-05-05$10.37/sh−20,743→ 2,514,415 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-05-04$10.37/sh−37,500→ 2,535,158 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-05-03$10.37/sh−79,475→ 2,572,658 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-05-02$10.38/sh−153,700→ 2,652,133 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-04-29$10.38/sh−69,230→ 2,805,833 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-04-28$10.38/sh−73,400→ 2,875,063 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-04-27$10.38/sh−47,396→ 2,948,463 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-04-26$10.38/sh−64,683→ 2,995,859 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-04-25$10.39/sh−27,668→ 3,060,542 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-04-22$10.39/sh−37,430→ 3,088,210 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-04-21$10.38/sh−62,200→ 3,125,640 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-04-20$10.39/sh−85,611→ 3,187,840 total
Sale
Checkmate Pharmaceuticals, Inc.
Common Stock
2022-04-19$10.42/sh−399,923→ 3,273,451 total
Conversion
Ventyx Biosciences, Inc.$VTYX
Common Stock
2021-10-25+3,684,769→ 3,684,769 total
Purchase
Ventyx Biosciences, Inc.$VTYX
Common Stock
2021-10-25$16.00/sh+312,500→ 3,997,269 total
Conversion
Ventyx Biosciences, Inc.$VTYX
Series B Preferred Stock
2021-10-25−395,027→ 0 total
Conversion
Ventyx Biosciences, Inc.$VTYX
Series A Preferred Stock
2021-10-25−3,289,742→ 0 total
Sale
Metacrine, Inc.
Common Stock
2021-10-25$1.49/sh−540,667→ 2,443,421 total
Sale
Metacrine, Inc.
Common Stock
2021-10-22$1.64/sh−75,035→ 2,984,088 total
Conversion
Elevation Oncology, Inc.
Series B Preferred Stock
2021-06-29−8,380,034→ 0 total
Purchase
Elevation Oncology, Inc.
Common Stock
2021-06-29$16.00/sh+625,000→ 2,608,167 total
Conversion
Elevation Oncology, Inc.
Common Stock
2021-06-29+1,983,167→ 1,983,167 total
Conversion
IPI Legacy Liquidation Co
Series D Redeemable Convertible Preferred Stock
2021-04-27−5,876,034→ 0 total
Conversion
IPI Legacy Liquidation Co
Series C-2 Redeemable Convertible Preferred Stock
2021-04-27−8,845,942→ 0 total
Conversion
IPI Legacy Liquidation Co
Common Stock
2021-04-27+2,309,791→ 2,309,791 total
Conversion
IPI Legacy Liquidation Co
Series C-1 Redeemable Convertible Preferred Stock
2021-04-27−13,233,885→ 0 total
Conversion
IPI Legacy Liquidation Co
5% Convertible Note due 2021
2021-04-27→ 0 total
Purchase
IPI Legacy Liquidation Co
Common Stock
2021-04-27$15.00/sh+450,000→ 2,759,791 total

Adelman Robert J

Recent Transactions

Companies

Recent Filings

Address